Evidence map›Paper›PMID 39854411›Full record

ArticlePloS one2025

Development of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome.

Richard W Heidebrecht, Thomas H Jozefiak, Harrison C Shain, Eugene M Skrabut, Debra Saunders, Nataliya Smith, Rheal A Towner, Robert Hurst

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richard W HeidebrechtGlycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.ORCID 0009-0005-4470-0206
Thomas H JozefiakGlycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.ORCID 0000-0001-8370-6102
Harrison C ShainGlycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.
Eugene M SkrabutGlycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.
Debra SaundersAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Nataliya SmithAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Rheal A TownerAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Robert HurstGlycologix, Inc., 100 Cummings Center, Beverly, Massachusetts, United States of America.

Funding

SuperGAGs for Intravesicular Treatment of Interstitial CystitisR43DK116356 · NIDDK · GLYCOLOGIX, LLC · PI HURST, ROBERT EVAN · 2018 to 2018
$288k
NIDDK NIH HHS R43 DK116356
6 · The paper itself

Abstract

Chemical modification of naturally derived glycosaminoglycans (GAGs) expands their potential utility for applications in soft tissue repair and regenerative medicine. Here we report the preparation of a novel crosslinked chondroitin sulfate (~200 to 2000 kilodaltons) that is both soluble in aqueous solution and microfilterable. We refer to these materials as "SuperGAGs." One can further conjugate these materials with diverse capture agents to further modify polymer properties and add new capabilities. A representative material (GLX-100) demonstrated durable restoration of bladder impermeability in a gold standard animal model of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Histologic examination of the animal bladders treated with a GLX-100 SuperGAG conjugated to biotin as a reporter demonstrated that the residence time of GLX-100 is superior to chondroitin sulfate (a product that is currently used for clinical treatment of patients with IC/BPS). As expected, this novel crosslinked GAG biopolymer was restricted to the luminal surface of the bladder wall. In this communication we describe a simple and versatile synthesis of a crosslinked glycosaminoglycan (GAG) biopolymer for soft tissue repair. Chondroitin sulfate (~12 kD) was crosslinked to form a water soluble and microfilterable polymer with approximately 200 to 2000 kD molecular weight. The synthesis presented here allows for control of molecular weight while avoiding formation of an extended block gel. Moreover, the procedure enables further chemical modification of the SuperGAG through the selection of a capture agent. A set of agents have been used, demonstrating the preparation of a family of SuperGAGs with diverse capabilities. We can optimize polymer properties, adjust adherence to various tissues, add reporters, and engage the biochemistry of surrounding tissues with peptides and other bioactives.

Indexed as

Chondroitin SulfatesCross-Linking ReagentsCystitis, InterstitialGlycosaminoglycansAnimalsDisease Models, AnimalFemaleHumansRatsUrinary BladderChondroitin SulfatesCross-Linking ReagentsGlycosaminoglycans

Identifiers

PMID39854411
PMCPMC11760559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.